Figure 1 Supplementary Material – Different doses of LMWH

Panel 1 – LMWH 4000 IU (40 mg)/0.4 ml

Differences between survival curves: not statistically significant

Panel 2 – LMWH 4000 IU (40 mg)/0.4 ml BID

Differences between survival curves: not statistically significant

Panel 3 – LMWH 4000 IU (40 mg)/0.4 ml BID

Differences between survival curves:
Log Rank (Mantel – Cox ) p=0.140;
Breslow (Generalized Wilcoxon) p=0.138;
Tarone-Ware p=0.139

Panel 4 – LMWH 4000 IU (40 mg)/0.4 ml BID

Differences between survival curves:
Log Rank (Mantel – Cox ) p=0.086;
Breslow (Generalized Wilcoxon) p=0.128;
Tarone-Ware p=0.109

Panel 5 – LMWH 6000 IU (60 mg)/0.6 ml

Differences between survival curves:
Log Rank (Mantel – Cox ) p=0.104;
Breslow (Generalized Wilcoxon) p=0.101; Tarone-Ware p=0.102

Panel 6 – LMWH 6000 IU (60 mg)/0.6 ml

Differences between survival curves:
Log Rank (Mantel – Cox ) p=0.099;
Breslow (Generalized Wilcoxon) p=0.106;
Tarone-Ware p=0.101

Panel 7 – LMWH anticoagulant dose

Differences between survival curves: not statistically significant
Breslow (Generalized Wilcoxon) p=0.091

Panel 8 – LMWH anticoagulant dose

Differences between survival curves:
Log Rank (Mantel – Cox ) p=0.025;
Breslow (Generalized Wilcoxon) p=0.013;
Tarone-Ware p=0.017

Panel 9 – LMWH any dose or NOAC

Differences between survival curves:
Log Rank (Mantel – Cox ) p=0.060;
Breslow (Generalized Wilcoxon) p=0.040;
Tarone-Ware p=0.049

Panel 10 – LMWH any dose or NOAC

Differences between survival curves:
Log Rank (Mantel – Cox ) p=0.001;
Breslow (Generalized Wilcoxon) p=0.001;
Tarone-Ware p=0.001
Figure 2 Supplementary Material – Treatments during admission

Panel 1 – Antiviral

Cumulative survival

Differences between survival curves:
Log Rank (Mantel – Cox) \( p = 0.019 \);
Breslow (Generalized Wilcoxon) \( p = 0.011 \);
Tarone-Ware \( p = 0.014 \)

Duration of follow-up (days)

Panel 2 – Antiviral

Cumulative survival

Differences between survival curves:
Log Rank (Mantel – Cox) \( p = 0.002 \);
Breslow (Generalized Wilcoxon) \( p = 0.001 \);
Tarone-Ware \( p = 0.001 \)

Duration of hospitalization (days)

Panel 3 – Hydroxychloroquine

Cumulative survival

Differences between survival curves:
Log Rank (Mantel – Cox) \( p = 0.001 \);
Breslow (Generalized Wilcoxon) \( p < 0.001 \);
Tarone-Ware \( p = 0.001 \)

Duration of follow-up (days)

Panel 4 – Hydroxychloroquine

Cumulative survival

Differences between survival curves:
Log Rank (Mantel – Cox) \( p = 0.001 \);
Breslow (Generalized Wilcoxon) \( p < 0.001 \);
Tarone-Ware \( p < 0.001 \)

Duration of hospitalization (days)

Panel 5 – Corticosteroid

Cumulative survival

Differences between survival curves:
Log Rank (Mantel – Cox) \( p = 0.001 \);
Breslow (Generalized Wilcoxon) \( p = 0.003 \);
Tarone-Ware \( p = 0.001 \)

Duration of follow-up (days)

Panel 6 – Corticosteroid

Cumulative survival

Differences between survival curves:
Log Rank (Mantel – Cox) \( p = 0.001 \);
Breslow (Generalized Wilcoxon) \( p < 0.001 \);
Tarone-Ware \( p < 0.001 \)

Duration of hospitalization (days)

Panel 7 – Tocilizumab

Cumulative survival

Differences between survival curves:
Log Rank (Mantel – Cox) \( p = 0.003 \);
Breslow (Generalized Wilcoxon) \( p = 0.002 \);
Tarone-Ware \( p = 0.003 \)

Duration of follow-up (days)

Panel 8 – Tocilizumab

Cumulative survival

Differences between survival curves:
Log Rank (Mantel – Cox) \( p < 0.001 \);
Breslow (Generalized Wilcoxon) \( p < 0.001 \);
Tarone-Ware \( p < 0.001 \)

Duration of hospitalization (days)
Figure legends

**Figure 1 – Supplementary material**
Legend as in Figure 4 of the main text

**Figure 2 – Supplementary material**
Kaplan-Meier survival curve for the different drug treatments during admission (excluding anticoagulant drugs)
Analysis run using group as factor; death as event and time to death/discharge or time to death/re-evaluation at follow up as time variable
Panel 1: treatment with lopinavir/ritonavir (red line) or no treatment with lopinavir/ritonavir (blue line), time to death/re-evaluation at follow up as time variable
Panel 2: treatment with lopinavir/ritonavir (red line) or no treatment with lopinavir/ritonavir (blue line), time to death/discharge as time variable
Panel 3: treatment with hydroxychloroquine (red line) or no treatment with hydroxychloroquine (blue line), time to death/re-evaluation at follow up as time variable
Panel 4: treatment with hydroxychloroquine (red line) or no treatment with hydroxychloroquine (blue line), time to death/discharge as time variable
Panel 5: treatment with dexamethasone (red line) or no treatment with dexamethasone (blue line), time to death/re-evaluation at follow up as time variable
Panel 6: treatment with dexamethasone (red line) or no treatment with dexamethasone (blue line), time to death/discharge as time variable
Panel 7: treatment with subcutaneous tocilizumab (red line), intravenous tocilizumab (green line) or no treatment with tocilizumab (blue line), time to death/re-evaluation at follow up as time variable
Panel 8: treatment with subcutaneous tocilizumab (red line), intravenous tocilizumab (green line) or no treatment with tocilizumab (blue line), time to death/discharge as time variable.